|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Zeng H and Zhang S: The
updated incidences and mortalities of major cancers in China, 2011.
Chin J Can. 34:502–507. 2015.
|
|
4
|
Tempero MA, Arnoletti JP, Behrman S,
Ben-Josef E, Benson AB III, Berlin JD, Cameron JL, Casper ES, Cohen
SJ, Duff M, et al: Pancreatic adenocarcinoma. J Natl Compr Canc
Netw. 8:972–1017. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Le N, Sund M and Vinci A; GEMS
collaborating group of Pancreas, : 2000.Prognostic and predictive
markers in pancreatic adenocarcinoma. Dig Liver Dis. 48:223–230,
2016. View Article : Google Scholar
|
|
6
|
Arnachellum RP, Cariou M, Nousbaum JB,
Jezequel J, Le Reste JY and Robaszkiewicz M: Pancreatic
Adenocarcinoma in the Finistère Area, france, between 2002 and 2011
(1002 Cases): Population characteristics, treatment and survival.
Pancreas. 45:953–960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cho JH, Ryu JK, Song SY, Hwang JH, Lee DK,
Woo SM, Joo YE, Jeong S, Lee SO, Park BK, et al: Prognostic
validity of the American joint committee on cancer and the European
neuroendocrine tumors staging classifications for pancreatic
neuroendocrine tumors: A retrospective nationwide multicenter study
in South Korea. Pancreas. 45:941–946. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu L, Xu HX, Wang WQ, Wu CT, Xiang JF,
Liu C, Long J, Xu J, Fu de L, Ni QX, et al: Serum CA125 is a novel
predictive marker for pancreatic cancer metastasis and correlates
with the metastasis-associated burden. Oncotarget. 7:5943–5956.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alsubai J, Matters GL, McGovern CO, Liao
J, Gilius EL and Smith JP: Germline mutation of the CCK receptor: A
novel biomarker for pancreas cancer. Clin Transl Gastroenterol.
7:e1342016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jeon YH, Park YH, Lee JH, Hong JH and Kim
IY: Selenoprotein W enhances skeletal muscle differentiation by
inhibiting TAZ binding to 14-3-3 protein. Biochim Biophys Acta.
1843:1356–1364. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chan SW, Lim CJ, Guo K, Ng CP, Lee I,
Hunziker W, Zeng Q and Hong W: A role for TAZ in migration,
invasion, and tumorigenesis of breast cancer cells. Cancer Res.
68:2592–2598. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lei QY, Zhang H, Zhao B, Zha ZY, Bai F,
Pei XH, Zhao S, Xiong Y and Guan KL: TAZ promotes cell
proliferation and epithelial-mesenchymal transition and is
inhibited by the hippo pathway. Mol Cell Biol. 28:2426–2436. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu H, Subramanian RR and Masters SC:
14-3-3 proteins: Structure, function, and regulation. Annu Rev
Pharmacol Toxicol. 40:617–647. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang S, Ma K, Chen L, Zhu H, Liang S, Liu
M and Xu N: TAZ promotes cell growth and inhibits Celastrol-induced
cell apoptosis. Biosci Rep. 36:pii: e003862016. View Article : Google Scholar
|
|
15
|
Morvaridi S, Dhall D, Greene MI, Pandol SJ
and Wang Q: Role of YAP and TAZ in pancreatic ductal adenocarcinoma
and in stellate cells associated with cancer and chronic
pancreatitis. Sci Rep. 5:167592015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xie D, Cui J, Xia T, Jia Z, Wang L, Wei W,
Zhu A, Gao Y, Xie K and Quan M: Hippo transducer TAZ promotes
epithelial mesenchymal transition and supports pancreatic cancer
progression. Oncotarget. 6:35949–35963. 2015.PubMed/NCBI
|
|
17
|
Chen M, Wang M, Xu S, Guo X and Jiang J:
Upregulation of miR-181c contributes to chemoresistance in
pancreatic cancer by inactivating the Hippo signaling pathway.
Oncotarget. 6:44466–44479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Higashi T, Hayashi H, Ishimoto T, Takeyama
H, Kaida T, Arima K, Taki K, Sakamoto K, Kuroki H, Okabe H, et al:
miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in
hepatocellular carcinoma cells. Br J Cancer. 113:252–258. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tuttle RM, Haugen B and Perrier ND:
Updated American Joint Committee on Cancer/Tumor-Node-Metastasis
Staging System for Differentiated and Anaplastic Thyroid Cancer
(Eighth Edition): What Changed and Why? Thyroid. 27:751–756. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li J, Yue Z, Xiong W, Sun P, You K and
Wang J: TXNIP overexpression suppresses proliferation and induces
apoptosis in SMMC7221 cells through ROS generation and MAPK pathway
activation. Oncol Rep. 37:3369–3376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sanger F, Nicklen S and Coulson AR: DNA
sequencing with chain-terminating inhibitors. Proc Natl Acad Sci
USA. 74:pp. 5463–5467. 1977; View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Duan LJ, Ding M, Hou LJ, Cui YT, Li CJ and
Yu DM: Long noncoding RNA TUG1 alleviates extracellular matrix
accumulation via mediating microRNA-377 targeting of PPARγ in
diabetic nephropathy. Biochem Biophys Res Commun. 484:598–604.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Welten SM, Bastiaansen AJ, de Jong RC, de
Vries MR, Peters EA, Boonstra MC, Sheikh SP, La Monica N,
Kandimalla ER, Quax PH and Nossent AY: Inhibition of 14q32
MicroRNAs miR-329, miR-487b, miR-494, and miR-495 increases
neovascularization and blood flow recovery after ischemia. Circ
Res. 115:696–708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shah VV, Soibam B, Ritter RA, Benham A,
Oomen J and Sater AK: Data on microRNAs and microRNA-targeted mRNAs
in Xenopus ectoderm. Data Brief. 9:699–703. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang F, Lu J, Peng X, Wang J, Liu X, Chen
X, Jiang Y, Li X and Zhang B: Integrated analysis of microRNA
regulatory network in nasopharyngeal carcinoma with deep
sequencing. J Exp Clin Cancer Res. 35:172016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shen WF, Hu YL, Uttarwar L, Passegue E and
Largman C: MicroRNA-126 regulates HOXA9 by binding to the homeobox.
Mol Cell Biol. 28:4609–4619. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Joladarashi D, Garikipati VNS,
Thandavarayan RA, Verma SK, Mackie AR, Khan M, Gumpert AM, Bhimaraj
A, Youker KA, Uribe C, et al: Enhanced cardiac regenerative ability
of stem cells after ischemia-reperfusion injury: Role of human
CD34+ cells deficient in MicroRNA-377. J Am Coll Cardiol.
66:2214–2226. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Q, Zeng L, Chen Y, Lian G, Qian C,
Chen S, Li J and Huang K: Pancreatic cancer epidemiology,
detection, and management. Gastroenterol Res Pract.
2016:89623212016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Halder G and Johnson RL: Hippo signaling:
Growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harvey K and Tapon N: The
Salvador-Warts-Hippo pathway-an emerging tumour-suppressor network.
Nat Rev Cancer. 7:182–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao B, Li L, Lei Q and Guan KL: The
Hippo-YAP pathway in organ size control and tumorigenesis: An
updated version. Genes Dev. 24:862–874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cordenonsi M, Zanconato F, Azzolin L,
Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR,
Poletti A, et al: The Hippo transducer TAZ confers cancer stem
cell-related traits on breast cancer cells. Cell. 147:759–772.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Varelas X: The Hippo pathway effectors TAZ
and YAP in development, homeostasis and disease. Development.
141:1614–1626. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie M, Zhang L, He CS, Hou JH, Lin SX, Hu
ZH, Xu F and Zhao HY: Prognostic significance of TAZ expression in
resected non-small cell lung cancer. J Thorac Oncol. 7:799–807.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yue G, Sun X, Gimenez-Capitan A, Shen J,
Yu L, Teixido C, Guan W, Rosell R, Liu B and Wei J: TAZ is highly
expressed in gastric signet ring cell carcinoma. Biomed Res Int.
2014:3930642014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang YP and Tang DX: Expression of
Yes-associated protein in liver cancer and its correlation with
clinicopathological features and prognosis of liver cancer
patients. Int J Clin Exp Med. 8:1080–1086. 2015.PubMed/NCBI
|
|
39
|
Kim JO, Song DW, Kwon EJ, Hong SE, Song
HK, Min CK and Kim DH: miR-185 plays an anti-hypertrophic role in
the heart via multiple targets in the calcium-signaling pathways.
PLoS One. 10:e01225092015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ma X, Shen D, Li H, Zhang Y, Lv X, Huang
Q, Gao Y, Li X, Gu L, Xiu S, Bao X, et al: MicroRNA-185 inhibits
cell proliferation and induces cell apoptosis by targeting VEGFA
directly in von Hippel-Lindau-inactivated clear cell renal cell
carcinoma. Urol Oncol. 33:169. e1–11. 2015. View Article : Google Scholar
|
|
41
|
Bao L, Fu X, Si M, Wang Y, Ma R, Ren X and
Lv H: MicroRNA-185 targets SOCS3 to inhibit beta-cell dysfunction
in diabetes. PLoS One. 10:e01160672015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fu P, DU F, Yao M, Lv K and Liu Y:
MicroRNA-185 inhibits proliferation by targeting c-Met in human
breast cancer cells. Exp Ther Med. 8:1879–1883. 2014.PubMed/NCBI
|
|
43
|
Wang R, Tian S, Wang HB, Chu DP, Cao JL,
Xia HF and Ma X: MiR-185 is involved in human breast carcinogenesis
by targeting Vegfa. FEBS Lett. 588:4438–4447. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Miller MK, Bang ML, Witt CC, Labeit D,
Trombitas C, Watanabe K, Granzier H, McElhinny AS, Gregorio CC and
Labeit S: The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and
DARP as a family of titin filament-based stress response molecules.
J Mol Biol. 333:951–964. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mosavi LK, Cammett TJ, Desrosiers DC and
Peng ZY: The ankyrin repeat as molecular architecture for protein
recognition. Protein Sci. 13:1435–1448. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wei J, Yu G, Shao G, Sun A, Chen M, Yang W
and Lin Q: CYR61 (CCN1) is a metastatic biomarker of gastric cardia
adenocarcinoma. Oncotarget. 7:31067–31078. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kuonen F, Secondini C and Ruegg C:
Molecular pathways: Emerging pathways mediating growth, invasion,
and metastasis of tumors progressing in an irradiated
microenvironment. Clin Cancer Res. 18:5196–5202. 2012. View Article : Google Scholar : PubMed/NCBI
|
